InvestWiser

ALK-Abelló A/S

ALK-BNasdaq CopenhagenHealthcareMarket value 49.0 bn DKK
243.00DKK −1.2%
last day · Price as of 18 November 2026

The answer first

Does ALK-Abelló beat the market?

No, ALK-Abelló has not beaten the market over the last year.

ALK-Abelló+4.5%København (OMXCGI)+13.9%
  • The ranking · Quality, value and trend combined

    Better than 60% of Nordic stocks

    • Quality95
    • Value9
    • Trend66

    No. 49 of 195 in healthcare

  • Expectations in the price

    High expectations

    For the share to return about 9% a year from today's price, the cash ALK-Abelló keeps must grow about 11% a year for 10 years.

Max for seven days

Follow ALK-Abelló with Aurora

Aurora lets you know at the next report. No card.

Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.

Follow your thesis

Follow your thesis on ALK-Abelló

From today, at a price of 243.00 DKK. Write why you follow ALK-Abelló, and choose what Aurora should tell you about.

What should Aurora follow?

Free, no card. The mission is ready when your account is.

Aurora tells you that something happened. What you do is your choice.

Ask Aurora about ALK-Abelló

Your first answer is free, no account needed.

Do you own ALK-Abelló, or are you thinking about it?

See it next to the rest of your portfolio, or build your first one with ALK-Abelló and a few more. Free, no card.

Past year against the exchange and Super Stock
ALK-Abelló+4.5%København (OMXCGI)+13.9%Super Stock+44.6%
14 November 202518 November 2026
All start at 0 % a year ago, with dividends. Super Stock is our model portfolio: the 20 highest-ranked Nordic stocks on quality, value and trend.

In short

  • ALK-Abelló has risen 4.5% over the past year, including dividends.
  • Overall, ALK-Abelló ranks better than 60% of Nordic stocks on quality, value and trend.
  • The largest fall over the past three years was 55.9%. The price is 10.1% below its peak now.

What do analysts think of ALK-Abelló?

Quality, value and trend

Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.

60

Quality, value and trend together. Better than 60% of Nordic stocks.

No. 49 of 195 in healthcare

Quality95
The company · Fundamentals: the accounts

High A solid company: it earns well on its money and has healthy finances.

No. 18 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50

  • Debt to equityBorrowings divided by equity0.07
  • Asset turnoverSales divided by everything the company owns0.70
  • Return on equityProfit divided by equity+19.5%
  • Cash conversionOperating cash flow divided by profit1.59

The ranking is built on equity ratio, ROA and how steadily profit grows.

Value9
The price · Valuation: the multiples

Low High price: buyers pay a lot today, often because they expect growth.

No. 140 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50

  • P/BPrice divided by equity7.5
  • P/SPrice divided by sales7.6
  • P/EPrice divided by earnings38.2
  • P/CFPrice divided by operating cash flow24.0

The ranking is built on P/E, P/B and P/S.

Trend66
The share price · Technical: the price trend

Medium The share price has moved about like most stocks over the last year.

No. 58 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50

  • 3 months+12.5%
  • 6 months−7.6%
  • 9 months+12.3%
  • 12 months+4.5%

The ranking is built on 3, 6 and 12–1 months.

Return and risk

1 month
+2.2%
3 years, per year
+47.5%
5 years, per year
+10.3%
10 years, per year
+18.3%
Largest fall, 3 years
−55.9%
From a peak to the bottom
From the peak now
−10.1%
How far the price is from the peak
Volatility, 1 year
26.0%
How much the price swings over a year
Beta, 1 year
0.42
How much the price moves when the market moves

Return with dividends reinvested.

The funds that own ALK-Abelló

24 funds we follow own ALK-Abelló. The share is how much of the fund the stock makes up.

  • Norway3
  • Sweden17
  • Denmark4
  • 1 ETF

From the funds' latest known holdings.

About ALK-Abelló

ALK-Abelló A/S is a company in healthcare, listed on Nasdaq Copenhagen. The share trades in DKK. It has around 2,600 employees.

ALK-Abelló A/S, an allergy solutions company, develops treatments for respiratory allergy, anaphylaxis, and food allergy and new disease areas in the European Union, the United Kingdom, Norway, Switzerland, the United States, Canada, Japan, China, and internationally. The company offers allergy immunotherapy products in the form of vaccines, injections, sublingual drops, and tablets for the treatment of various allergies, including grass and tree pollen, house dust mites, ragweed, Japanese cedar, peanuts, and tree nuts; adrenaline nasal sprays for emergency treatment of anaphylaxis and acute flares in chronic spontaneous urticaria; and ALK 014, a biologic for food allergies.

See the full analysis of ALK-Abelló.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

Free forever · No card

Other healthcare stocks on Nasdaq Copenhagen

Explore the stock market